Stocks rise for Aerie, BioCryst following positive trial results

Duke University spinout Aerie Pharmaceuticals ’ (Nasdaq: AERI) as well as Durham-based BioCryst Pharmaceuticals (Nasdaq: BCRX) both saw stock prices jump Thursday on the heels of positive trial results. Shares of both companies were up about 30 percent Thursday afternoon, with shares of Aerie trading just under $53 and shares of BioCryst tra ding close to $7. Late Wednesday, Aerie announced positive Phase 2 trial results for glaucoma product Roclatan. Vicente Anido Jr., chairman and CEO of Aerie,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news